Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group)

▪ Introduction: The combined use of genetic markers and minimal residual disease (MRD) assessment identifies CLL patients (pts) with a poor outcome after front line chemoimmunotherapy. The CLLM1 study was initiated to evaluate lenalidomide as a maintenance treatment versus (vs) placebo in a double-b...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2016-12, Vol.128 (22), p.229-229
Main Authors: Fink, Anna Maria, Bahlo, Jasmin, Sandra, Robrecht, Al-Sawaf, Othman, Aldaoud, Ali, Hebart, Holger, Jentsch-Ulrich, Kathleen, Doerfel, Steffen, Fischer, Kirsten, Wendtner, Clemens Martin, Noesslinger, Thomas, Ghia, Paolo, Bosch, Francesc, Kater, Arnon P., Kreuzer, Karl-Anton, Dohner, Hartmut, Kneba, Michael, Stilgenbauer, Stephan, Boettcher, Sebastian, Eichhorst, Barbara, Hallek, Michael
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:▪ Introduction: The combined use of genetic markers and minimal residual disease (MRD) assessment identifies CLL patients (pts) with a poor outcome after front line chemoimmunotherapy. The CLLM1 study was initiated to evaluate lenalidomide as a maintenance treatment versus (vs) placebo in a double-blind fashion. The primary endpoint was progression free survival (PFS) by an independent review. Methods: Pts who achieved at least a partial response after at least 4 cycles of front line chemoimmunotherapy were defined as high risk for progression if they had MRD levels of ≥10-2 or MRD levels of ≥10-4 to
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V128.22.229.229